Biomea Fusion, Inc. Common Stock BMEA · Stock Open Biomea Fusion, Inc. Common Stock in new tab
Analyst price targets
Recent rating changes, newest first
Biomea Fusion, Inc. Common Stock Analysis (BMEA)
Is Biomea Fusion, Inc. Common Stock a good investment? Biomea Fusion, Inc. Common Stock (BMEA) is currently trading at 0.8689 USD. Market analysts have a consensus price target of 7.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: Biomea Fusion, Inc. Common Stock is expected to release its next earnings report on Nov. 3, 2026. The market consensus estimate for Forward EPS is -0.94.
Investor FAQ
Does Biomea Fusion, Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Biomea Fusion, Inc. Common Stock?
Biomea Fusion, Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 3, 2026. The company currently has a trailing EPS of -0.29.
Company Profile
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Community Discussion